27384676|t|Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149
27384676|a|To explore a more effective treatment for newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), we conducted a phase 4 study of the cisplatin, dexamethasone, gemcitabine, pegaspargase (DDGP) regimen. The primary end point was the 2-year progression-free survival (PFS) after the protocol treatment. Secondary endpoints included response rate (RR), overall survival (OS) and median survival time (MST). The interim analysis included data only from March 2011 to September 2013, who received six cycles of DDGP chemotherapy. A total of 25 eligible patients were enrolled. Seventeen patients (17/24, 70.83%) achieved complete response (CR) and four (4/24, 16.67%) achieved partial response (PR), three (3/24, 12.50%) had progressive disease (PD). The RR after treatment was 87.50%. After a median follow-up duration of 24.67 months (range 4-48 months). The 2-year PFS and OS rate were 61.80% (95% CI, 42.00% to 81.60%) and 68.50 % (95% CI, 48.70% to 88.30%), respectively. The MST was 36.55 months (95% CI, 29.41 months to 43.70 months). Grade 3/4 leukopenia occurred in fourteen patients (58.33%) and grade 3/4 thrombocytopenia occurred in eleven patients (45.83%). Twelve patients (50.00%) experienced Activated Partial Phromboplastin Ptime (APTT) elongation and fourteen patients (58.33%) experienced hypofibrinogenemia. In conclusion, DDGP regimen is an effective and tolerated treatment for newly diagnosed, advanced-stage ENKTL. This trial was registered at www.ClinicalTrials.gov as #NCT01501149.
27384676	0	8	Efficacy	T080	C1280519
27384676	13	19	safety	T080	C0678800
27384676	23	32	cisplatin	T121,T197	C0008838
27384676	34	47	dexamethasone	T109,T121	C0011777
27384676	49	60	gemcitabine	T114,T121	C0045093
27384676	65	77	pegaspargase	T116,T121,T126	C0071568
27384676	79	83	DDGP	T121	C1254351
27384676	85	92	regimen	T061	C0040808
27384676	96	111	newly diagnosed	T080	C1518321
27384676	113	127	advanced-stage	T080	C0205179
27384676	128	169	extranodal natural killer/T-cell lymphoma	T191	C1955906
27384676	171	178	interim	T079	C2827738
27384676	179	187	analysis	T062	C0936012
27384676	193	200	phase 4	T079	C0439562
27384676	201	206	study	T062	C2603343
27384676	237	246	effective	T080	C1704419
27384676	247	256	treatment	T169	C0039798
27384676	261	276	newly diagnosed	T080	C1518321
27384676	278	292	advanced-stage	T080	C0205179
27384676	293	346	extranodal natural killer/T-cell lymphoma, nasal type	T191	C0392788
27384676	348	353	ENKTL	T191	C0392788
27384676	371	378	phase 4	T079	C0439562
27384676	379	384	study	T062	C2603343
27384676	392	401	cisplatin	T121,T197	C0008838
27384676	403	416	dexamethasone	T109,T121	C0011777
27384676	418	429	gemcitabine	T114,T121	C0045093
27384676	431	443	pegaspargase	T116,T121,T126	C0071568
27384676	445	449	DDGP	T121	C1254351
27384676	451	458	regimen	T061	C0040808
27384676	472	481	end point	T080	C2349179
27384676	497	522	progression-free survival	T081	C0242792
27384676	524	527	PFS	T081	C0242792
27384676	539	557	protocol treatment	T061	C0040808
27384676	569	578	endpoints	T080	C2349179
27384676	588	601	response rate	T079	C0237629
27384676	603	605	RR	T079	C0237629
27384676	608	624	overall survival	T081	C4086681
27384676	626	628	OS	T081	C4086681
27384676	634	654	median survival time	T079	C2986586
27384676	656	659	MST	T079	C2986586
27384676	666	673	interim	T079	C2827738
27384676	674	682	analysis	T062	C0936012
27384676	692	696	data	T078	C1511726
27384676	741	749	received	T080	C1514756
27384676	764	768	DDGP	T121	C1254351
27384676	769	781	chemotherapy	T061	C3665472
27384676	797	805	eligible	T080	C1548635
27384676	806	814	patients	T101	C0030705
27384676	840	848	patients	T101	C0030705
27384676	874	891	complete response	T033	C1275810
27384676	893	895	CR	T033	C1275810
27384676	930	946	partial response	T033	C1521726
27384676	948	950	PR	T033	C1521726
27384676	978	997	progressive disease	T047	C1335499
27384676	999	1001	PD	T047	C1335499
27384676	1008	1010	RR	T079	C0237629
27384676	1017	1026	treatment	T169	C0039798
27384676	1047	1053	median	T081	C0876920
27384676	1054	1063	follow-up	T058	C1522577
27384676	1064	1072	duration	T079	C0449238
27384676	1082	1088	months	T079	C0439231
27384676	1101	1107	months	T079	C0439231
27384676	1121	1124	PFS	T081	C0242792
27384676	1129	1136	OS rate	T081	C0038954
27384676	1154	1156	CI	T081	C0009667
27384676	1193	1195	CI	T081	C0009667
27384676	1234	1237	MST	T079	C2986586
27384676	1248	1254	months	T079	C0439231
27384676	1260	1262	CI	T081	C0009667
27384676	1270	1276	months	T079	C0439231
27384676	1286	1292	months	T079	C0439231
27384676	1295	1300	Grade	T185	C0441800
27384676	1305	1315	leukopenia	T047	C0023530
27384676	1316	1324	occurred	T079	C2745955
27384676	1337	1345	patients	T101	C0030705
27384676	1359	1364	grade	T185	C0441800
27384676	1369	1385	thrombocytopenia	T047	C0040034
27384676	1386	1394	occurred	T079	C2745955
27384676	1405	1413	patients	T101	C0030705
27384676	1431	1439	patients	T101	C0030705
27384676	1461	1499	Activated Partial Phromboplastin Ptime	T059	C0030605
27384676	1501	1505	APTT	T059	C0030605
27384676	1507	1517	elongation	T033	C0240671
27384676	1531	1539	patients	T101	C0030705
27384676	1561	1579	hypofibrinogenemia	T047	C0553681
27384676	1596	1600	DDGP	T121	C1254351
27384676	1601	1608	regimen	T061	C0040808
27384676	1615	1624	effective	T080	C1704419
27384676	1629	1638	tolerated	T033	C0013220
27384676	1639	1648	treatment	T169	C0039798
27384676	1653	1668	newly diagnosed	T080	C1518321
27384676	1670	1684	advanced-stage	T080	C0205179
27384676	1685	1690	ENKTL	T191	C0392788
27384676	1697	1702	trial	T062	C0008976
27384676	1707	1717	registered	T058	C1514821
27384676	1721	1743	www.ClinicalTrials.gov	T170	C2349146